CABs LAT CAB (2021-present)

Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments

Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. A survey sought to understand the acceptability of approaches to long-acting HCV treatment.

The results, published in Clinical Infectious Diseases, pointed to high acceptability of long-acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C.